225 related articles for article (PubMed ID: 33729159)
1. Topological signatures in regulatory network enable phenotypic heterogeneity in small cell lung cancer.
Chauhan L; Ram U; Hari K; Jolly MK
Elife; 2021 Mar; 10():. PubMed ID: 33729159
[TBL] [Abstract][Full Text] [Related]
2. Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity.
Udyavar AR; Wooten DJ; Hoeksema M; Bansal M; Califano A; Estrada L; Schnell S; Irish JM; Massion PP; Quaranta V
Cancer Res; 2017 Mar; 77(5):1063-1074. PubMed ID: 27932399
[TBL] [Abstract][Full Text] [Related]
3. Landscape of epithelial-mesenchymal plasticity as an emergent property of coordinated teams in regulatory networks.
Hari K; Ullanat V; Balasubramanian A; Gopalan A; Jolly MK
Elife; 2022 Oct; 11():. PubMed ID: 36269057
[TBL] [Abstract][Full Text] [Related]
4. System analysis identifies distinct and common functional networks governed by transcription factor ASCL1, in glioma and small cell lung cancer.
Donakonda S; Sinha S; Dighe SN; Rao MRS
Mol Biosyst; 2017 Jul; 13(8):1481-1494. PubMed ID: 28742165
[TBL] [Abstract][Full Text] [Related]
5. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.
Horie M; Saito A; Ohshima M; Suzuki HI; Nagase T
Cancer Sci; 2016 Dec; 107(12):1755-1766. PubMed ID: 27627196
[TBL] [Abstract][Full Text] [Related]
6. MYC, MAX, and small cell lung cancer.
Rudin CM; Poirier JT
Cancer Discov; 2014 Mar; 4(3):273-4. PubMed ID: 24596200
[TBL] [Abstract][Full Text] [Related]
7. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.
Romero OA; Torres-Diz M; Pros E; Savola S; Gomez A; Moran S; Saez C; Iwakawa R; Villanueva A; Montuenga LM; Kohno T; Yokota J; Sanchez-Cespedes M
Cancer Discov; 2014 Mar; 4(3):292-303. PubMed ID: 24362264
[TBL] [Abstract][Full Text] [Related]
8. Identification of functional modules that correlate with phenotypic difference: the influence of network topology.
Hung JH; Whitfield TW; Yang TH; Hu Z; Weng Z; DeLisi C
Genome Biol; 2010; 11(2):R23. PubMed ID: 20187943
[TBL] [Abstract][Full Text] [Related]
9. Robustness in phenotypic plasticity and heterogeneity patterns enabled by EMT networks.
Hebbar A; Moger A; Hari K; Jolly MK
Biophys J; 2022 Oct; 121(19):3600-3615. PubMed ID: 35859419
[TBL] [Abstract][Full Text] [Related]
10. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer.
Huang YH; Klingbeil O; He XY; Wu XS; Arun G; Lu B; Somerville TDD; Milazzo JP; Wilkinson JE; Demerdash OE; Spector DL; Egeblad M; Shi J; Vakoc CR
Genes Dev; 2018 Jul; 32(13-14):915-928. PubMed ID: 29945888
[TBL] [Abstract][Full Text] [Related]
11. Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer.
Udyavar AR; Hoeksema MD; Clark JE; Zou Y; Tang Z; Li Z; Li M; Chen H; Statnikov A; Shyr Y; Liebler DC; Field J; Eisenberg R; Estrada L; Massion PP; Quaranta V
BMC Syst Biol; 2013; 7 Suppl 5(Suppl 5):S1. PubMed ID: 24564859
[TBL] [Abstract][Full Text] [Related]
12. Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data.
Wang E; Zaman N; Mcgee S; Milanese JS; Masoudi-Nejad A; O'Connor-McCourt M
Semin Cancer Biol; 2015 Feb; 30():4-12. PubMed ID: 24747696
[TBL] [Abstract][Full Text] [Related]
13. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.
Ogino A; Choi J; Lin M; Wilkens MK; Calles A; Xu M; Adeni AE; Chambers ES; Capelletti M; Butaney M; Gray NS; Gokhale PC; Palakurthi S; Kirschmeier P; Oxnard GR; Sholl LM; Jänne PA
Mol Oncol; 2021 Jan; 15(1):27-42. PubMed ID: 32191822
[TBL] [Abstract][Full Text] [Related]
14. Small cell lung cancer: significance of RB alterations and TTF-1 expression in its carcinogenesis, phenotype, and biology.
Kitamura H; Yazawa T; Sato H; Okudela K; Shimoyamada H
Endocr Pathol; 2009; 20(2):101-7. PubMed ID: 19390995
[TBL] [Abstract][Full Text] [Related]
15. Unraveling phenotypic plasticity and evolution in small cell lung cancer.
Nath A
Cell Syst; 2022 Sep; 13(9):687-689. PubMed ID: 36137510
[TBL] [Abstract][Full Text] [Related]
16. A global view of regulatory networks in lung cancer: An approach to understand homogeneity and heterogeneity.
Lu J; Wang W; Xu M; Li Y; Chen C; Wang X
Semin Cancer Biol; 2017 Feb; 42():31-38. PubMed ID: 27894849
[TBL] [Abstract][Full Text] [Related]
17. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.
Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L
Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118
[TBL] [Abstract][Full Text] [Related]
18. TEAD and YAP regulate the enhancer network of human embryonic pancreatic progenitors.
Cebola I; Rodríguez-Seguí SA; Cho CH; Bessa J; Rovira M; Luengo M; Chhatriwala M; Berry A; Ponsa-Cobas J; Maestro MA; Jennings RE; Pasquali L; Morán I; Castro N; Hanley NA; Gomez-Skarmeta JL; Vallier L; Ferrer J
Nat Cell Biol; 2015 May; 17(5):615-626. PubMed ID: 25915126
[TBL] [Abstract][Full Text] [Related]
19. Multi-stability in cellular differentiation enabled by a network of three mutually repressing master regulators.
Duddu AS; Sahoo S; Hati S; Jhunjhunwala S; Jolly MK
J R Soc Interface; 2020 Sep; 17(170):20200631. PubMed ID: 32993428
[TBL] [Abstract][Full Text] [Related]
20. Systems-level network modeling deciphers the master regulators of phenotypic plasticity and heterogeneity in melanoma.
Pillai M; Jolly MK
iScience; 2021 Oct; 24(10):103111. PubMed ID: 34622164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
